Carmot Therapeutics, Inc.
Clinical trials sponsored by Carmot Therapeutics, Inc., explained in plain language.
A biotech developing drugs for metabolic diseases like obesity.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
-
New weekly shot shows promise for major weight loss
Disease control CompletedThis study tested a new drug called enicepatide (CT-388) given as a weekly injection for 48 weeks. It involved 469 adults with obesity or overweight who also had at least one weight-related health problem like high blood pressure or prediabetes. The goal was to see how much weigh…
Phase: PHASE2 • Sponsor: Carmot Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
New shot could help diabetics lose weight and lower blood sugar
Disease control CompletedThis study tested a new daily injection called CT-868 in 103 overweight or obese adults with type 2 diabetes. Participants received either the drug or a placebo for 26 weeks. The main goal was to see if CT-868 could lower blood sugar levels (HbA1c) and help with weight loss.
Phase: PHASE2 • Sponsor: Carmot Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
New peptide drug shows promise for obesity and diabetes in early trial
Disease control CompletedThis early-stage trial tested a new drug called CT-388 in 129 overweight or obese adults, including some with type 2 diabetes. The study aimed to check the drug's safety and how the body processes it, while also measuring weight loss and blood sugar changes. Participants received…
Phase: PHASE1 • Sponsor: Carmot Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC